Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03998163 · ClinicalTrials.gov registry record · Phase 3
CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
A Phase 3 study, sponsored by Cara Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 222
- Enrollment target
NCT03998163 is a Phase 3 study that has completed, run by Cara Therapeutics. The registered enrollment target is 222 participants.
The verdict
NCT03998163, a Phase 3 study, has completed, sponsored by Cara Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 222 participants
- Enrollment target
Study Summary
This is a multicenter, open-label study to evaluate the safety and effectiveness of intravenous (IV) CR845 at a dose of 0.5 mcg/kg administered after each dialysis session. The study includes an up to 12-week Treatment Period.
Interventions
- DRUG CR845 0.5 mcg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 222 participants |
| Start Date | 2019-05-06 |
| Est. Completion | 2020-03-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03998163
The ClinicalTrials.gov registry entry for NCT03998163 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 222 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cara Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CR845 0.5 mcg/kg is the first listed.
NCT03998163 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03998163 about?
NCT03998163 is a clinical study titled "CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus". This is a multicenter, open-label study to evaluate the safety and effectiveness of intravenous (IV) CR845 at a dose of 0.5 mcg/kg administered after each dialysis session. The study includes an up to 12-week Treatment Period.
What is the current status of trial NCT03998163?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 222 participants. The study started on 2019-05-06. Estimated completion is 2020-03-06.
What interventions are being tested in trial NCT03998163?
The interventions under investigation include: CR845 0.5 mcg/kg (DRUG).
Who is sponsoring clinical trial NCT03998163?
This trial is sponsored by Cara Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.